SCHEMBL13153178

SCHEMBL13153178

CC(O)C(N)CCC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
ALOX15 P16050 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39
GABRB2 P47870 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRE P78334 2/20 0.39
GABRA6 Q16445 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10098471 1.00 KMT2A (0.48) KMT2AALOX15BLMPMP22DPP4
SCHEMBL16103418 1.00 KMT2A (0.48) KMT2AALOX15BLMPMP22DPP4
SCHEMBL16103399 0.83 ALOX15 (0.50) KMT2AALOX15BLMPMP22DPP4
SCHEMBL10098463 0.83 ALOX15 (0.50) KMT2AALOX15BLMPMP22DPP4
SCHEMBL944667 0.81 GABRP (0.62) KMT2ABLMPMP22DPP4DPP8
SCHEMBL21846798 0.81 ALDH1A1 (0.41) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL18576039 0.81 GABRP (0.62) KMT2ABLMPMP22DPP4DPP8
SCHEMBL15871670 0.81 GABRP (0.62) KMT2ABLMPMP22DPP4DPP8
SCHEMBL8509751 0.81 GABRP (0.62) KMT2ABLMPMP22DPP4DPP8
SCHEMBL17135504 0.81 GABRP (0.62) KMT2ABLMPMP22DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105431447-A Small molecule modulators of PCSK9 and methods of use thereof ADAERATA LTD PARTNERSHIP 2016-03-23 CN disclosed
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF NUCHEM THERAPEUTICS (CA) 2016-02-04 US disclosed
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF NUCHEM THERAPEUTICS (CA) 2016-02-04 US disclosed
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF NUCHEM THERAPEUTICS (CA) 2016-02-04 US disclosed
EP-2961765-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF Adaerata, Limited Partnership (CA) 2016-01-06 EP disclosed
WO-2014139008-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF ADAERATA, LIMITED PARTNERSHIP (CA) 2014-09-18 WO disclosed
WO-2014139008-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF ADAERATA, LIMITED PARTNERSHIP (CA) 2014-09-18 WO disclosed
WO-2010118309-A2 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031935-A1 SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 KMT2A 1879/4885ALOX15 733/4885BLM 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.